Last updated: February 8, 2026
What is the scope of the case?
Biogen Inc. alleges patent infringement against Teva Pharmaceuticals Development Inc., asserting Teva's production of generic versions of its multiple sclerosis drug, Tecfidera (dimethyl fumarate), infringes patents held by Biogen. The lawsuit was filed in the District of Delaware on January 25, 2021.
What patents are at issue?
Biogen's Complaint targets two patents:
- US Patent No. 8,399,514 (“'514 Patent”), issued in March 2013, covering methods of treating multiple sclerosis with dimethyl fumarate.
- US Patent No. 8,679,753 (“'753 Patent”), issued in March 2014, directed at particular formulations.
Both patents are assigned to Biogen and are critical for Tecfidera's market exclusivity.
What are the key allegations?
Biogen claims Teva infringes these patents by manufacturing and selling generic dimethyl fumarate products, which violate the asserted patents. The complaint includes allegations that Teva's ANDA (abbreviated new drug application) filing with its Paragraph IV certification constitutes patent infringement under 35 U.S.C. § 271(e)(2).
What are the procedural developments?
- Filing date: January 25, 2021.
- Teva's response: Filed an ANDA seeking approval for generic dimethyl fumarate and submitted Paragraph IV certifications in September 2020.
- Infringement contentions: Biogen responded with a notice of patent infringement and initiated the lawsuit to block Teva’s marketing of a generic version.
What is the litigation landscape?
In patent litigations involving biologics and complex small molecules like Tecfidera, courts scrutinize the validity and infringement of method and formulation patents. These cases often involve:
- Claim construction disputes: Precise interpretation of patent language.
- Invalidity challenges: Based on obviousness, anticipation, or lack of patentable subject matter.
- Settlement risk: Settlements often involve exclusivity licenses or patent challenges.
Legal and strategic implications
- Patent strength: Biogen’s patents are considered robust, but generic challengers frequently invoke invalidity defenses.
- Market impact: If Teva succeeds, it could secure substantial market share for generic dimethyl fumarate products, shaving years off Biogen's exclusivity.
- Regulatory considerations: Paragraph IV certifications trigger 180-day exclusivity for first filer, incentivizing patent challenges.
Potential outcomes and timelines
- Proceedings: Judge Andrews has assigned the case to a standard patent schedule.
- Possible resolutions: Summary judgment on validity or infringement, trial (expected in 2023), or settlement.
- Status checks: The case remains active; no dispositive motions filed yet.
Key Takeaways
- The case hinges on patent validity and infringement of Biogen's formulations and method patents.
- Teva's Paragraph IV certification indicates a challenge to patent validity, motivating patent infringement litigation.
- The outcome will influence Tecfidera’s market exclusivity timeline, with potential to accelerate entry of generic competition.
- Courts will examine patent claim scope, prior art references, and Teva's technical formulations.
- The case exemplifies the ongoing patent battles in the biosimilars and specialty drug space.
FAQs
1. What is a Paragraph IV certification?
It is a declaration by a generic manufacturer asserting that a patent listed in the Orange Book for an branded drug is invalid or not infringed, triggering patent litigation.
2. How does patent validity get challenged in court?
Defendants argue patents are obvious, anticipated, or lack novelty, supported by prior art references or procedural deficiencies.
3. What implications does this case have for Tecfidera?
A ruling favoring Teva could lead to early market entry of generic dimethyl fumarate, affecting Biogen’s revenue.
4. How long do patent litigations typically last?
They can extend from 1 to 3 years, depending on complexity, motions, and court schedules.
5. What strategic moves are prevalent in such patent cases?
Patent holders seek preliminary injunctions or stay of FDA approval, while challengers pursue invalidity defenses or settlement negotiations.
Sources
[1] U.S. District Court for the District of Delaware, Case No. 1:21-cv-00389, Docket records.
[2] FDA Orange Book, Biogen Tecfidera Patent Listing.
[3] Patent filings and certificates, USPTO.
